BR112015011299A2 - saquinavir-no para imunomodulação - Google Patents
saquinavir-no para imunomodulaçãoInfo
- Publication number
- BR112015011299A2 BR112015011299A2 BR112015011299A BR112015011299A BR112015011299A2 BR 112015011299 A2 BR112015011299 A2 BR 112015011299A2 BR 112015011299 A BR112015011299 A BR 112015011299A BR 112015011299 A BR112015011299 A BR 112015011299A BR 112015011299 A2 BR112015011299 A2 BR 112015011299A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- immunomodulation
- saquinavir
- diseases
- autoimmune
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000026872 Addison Disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 abstract 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 1
- 206010004659 Biliary cirrhosis Diseases 0.000 abstract 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010018634 Gouty Arthritis Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000001204 Hashimoto Disease Diseases 0.000 abstract 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 abstract 1
- 229960001852 saquinavir Drugs 0.000 abstract 1
- 208000010157 sclerosing cholangitis Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728330P | 2012-11-20 | 2012-11-20 | |
| PCT/EP2013/074264 WO2014079868A1 (en) | 2012-11-20 | 2013-11-20 | Saquinavir-no for immunomodulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015011299A2 true BR112015011299A2 (pt) | 2017-07-11 |
Family
ID=49759262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015011299A BR112015011299A2 (pt) | 2012-11-20 | 2013-11-20 | saquinavir-no para imunomodulação |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150283127A1 (https=) |
| EP (1) | EP2922545B1 (https=) |
| JP (1) | JP6283680B2 (https=) |
| KR (1) | KR20150084862A (https=) |
| CN (1) | CN104822379B (https=) |
| AU (1) | AU2013349804A1 (https=) |
| BR (1) | BR112015011299A2 (https=) |
| CA (1) | CA2891771A1 (https=) |
| IL (1) | IL238866A0 (https=) |
| MX (1) | MX2015006249A (https=) |
| WO (1) | WO2014079868A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127858A (zh) * | 2014-07-26 | 2014-11-05 | 滨州医学院 | 甲磺酸沙奎拉韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999063816A1 (en) * | 1998-06-09 | 1999-12-16 | Embro William J | Method and composition for the treatment of epidermal irritations and infections |
| FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
| WO2003051361A1 (en) * | 2001-12-14 | 2003-06-26 | Cedars-Sinai Medical Center | Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation |
| HRP20140929T1 (hr) * | 2008-08-01 | 2014-12-05 | Onconox Aps | Antitumorska svojstva no-modificiranih inhibitora proteaze |
| WO2012088305A1 (en) * | 2010-12-22 | 2012-06-28 | The Feinstein Institute For Medical Research | Methods for treating systemic lupus erythematosus using hiv protease inhibitors |
-
2013
- 2013-11-20 AU AU2013349804A patent/AU2013349804A1/en not_active Abandoned
- 2013-11-20 KR KR1020157013049A patent/KR20150084862A/ko not_active Withdrawn
- 2013-11-20 EP EP13802901.2A patent/EP2922545B1/en not_active Not-in-force
- 2013-11-20 JP JP2015542309A patent/JP6283680B2/ja not_active Expired - Fee Related
- 2013-11-20 WO PCT/EP2013/074264 patent/WO2014079868A1/en not_active Ceased
- 2013-11-20 CN CN201380060071.4A patent/CN104822379B/zh not_active Expired - Fee Related
- 2013-11-20 CA CA2891771A patent/CA2891771A1/en not_active Abandoned
- 2013-11-20 MX MX2015006249A patent/MX2015006249A/es unknown
- 2013-11-20 BR BR112015011299A patent/BR112015011299A2/pt not_active IP Right Cessation
- 2013-11-20 US US14/443,402 patent/US20150283127A1/en not_active Abandoned
-
2015
- 2015-05-18 IL IL238866A patent/IL238866A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2922545B1 (en) | 2016-09-21 |
| WO2014079868A1 (en) | 2014-05-30 |
| CA2891771A1 (en) | 2014-05-30 |
| IL238866A0 (en) | 2015-06-30 |
| EP2922545A1 (en) | 2015-09-30 |
| JP2015537023A (ja) | 2015-12-24 |
| HK1212895A1 (zh) | 2016-06-24 |
| CN104822379B (zh) | 2017-08-25 |
| JP6283680B2 (ja) | 2018-02-21 |
| AU2013349804A1 (en) | 2015-06-04 |
| KR20150084862A (ko) | 2015-07-22 |
| MX2015006249A (es) | 2015-12-03 |
| US20150283127A1 (en) | 2015-10-08 |
| CN104822379A (zh) | 2015-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003008A (es) | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos. | |
| MY165884A (en) | Methods of treatment using selective bcl-2 inhibitors | |
| WO2015195862A8 (en) | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| EA201490357A1 (ru) | Индазолы | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| HK1201519A1 (en) | Inhibitors of phosphodiesterase type 10a | |
| IL259877A (en) | Adeno-type viral vectors used to treat spinal muscular atrophy | |
| ATE512954T1 (de) | Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine | |
| GT201200257A (es) | Composiciones sólidas | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| PH12013502033A1 (en) | Pyrimidine derivatives for the treatment of viral infections | |
| CL2008000307A1 (es) | Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc. | |
| DK3486320T3 (da) | Raav-guanylatcyklase-sammensætninger og fremgangsmåder til behandling af lebers kongenitte amaurose-1 (lca1) | |
| WO2013056684A3 (zh) | 作为dhodh抑制剂的噻唑衍生物及其应用 | |
| EA201171210A1 (ru) | Производные оксадиазола | |
| GEAP201914563A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| WO2015195863A8 (en) | Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide | |
| IN2014CN00572A (https=) | ||
| NZ715903A (en) | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | |
| BR112017005564A2 (pt) | forma de cristal de bissulfato de inibidor de jak e método de preparação do mesmo | |
| HUE063528T2 (hu) | Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére | |
| NZ620074A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| BR112015011299A2 (pt) | saquinavir-no para imunomodulação | |
| EA201590006A1 (ru) | Комбинация терапевтических средств для лечения инфекции, вызванной вирусом гепатита c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |